Athira Pharma, Inc. (NASDAQ:ATHA) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. On September 18, 2025, ATHA will undergo a reverse stock split, exchanging 1 share for every 10 shares. This move, approved by stockholders, aims to consolidate shares and potentially enhance the stock's marketability.
The reverse stock split will officially take effect on September 17, 2025, at 5:00 p.m. Eastern Time. Following this, Athira's common stock will trade on a split-adjusted basis on the Nasdaq Capital Market starting September 18, 2025, under the same ticker symbol "ATHA". This strategic decision was made during the Annual Meeting of Stockholders on May 29, 2025.
Currently, ATHA's stock is priced at $0.38, showing a slight increase of 0.29% or $0.0011. The stock has experienced fluctuations today, with a low of $0.35 and a high of $0.40. Over the past year, ATHA has seen a high of $0.83 and a low of $0.22, indicating significant volatility.
Athira Pharma's market capitalization is approximately $15.1 million, with a trading volume of 586,605 shares on the NASDAQ exchange. The reverse stock split could impact these figures by reducing the number of shares outstanding, potentially increasing the stock price and attracting more investors.
